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MicroRNAs are involved in the regulation of various pathophysiological processes such as 
immune regulation and cancer. Next-generation sequencing methods enable us to monitor 
their presence in various types of samples but we need flexible methods for validating 
datasets generated by high throughput methods.  
Here we describe the detailed protocols to be used with our MiRNA Primer Design Tool 
assay design system. The presented methods allow the flexible design of the oligonucleotides 
needed for the RT-qPCR detection of any variant of small regulatory RNA molecules from 
virtually any species. This method can be used to measure miRNA levels from formalin-fixed, 
paraffin-embedded (FFPE) samples and various body fluids. As an example, we show the 
results of the hsa-miR-515-3p, hsa-miR-325, and hsa-miR-155 quantification using a specific 
UPL probe (Universal Probe Library) and a stem-loop RT-qPCR assay. The small nucleolar 
RNA RNU43 is used as endogenous control for normalization of the results. Urine from 
healthy pregnant women and FFPE samples from patients diagnosed with colorectal cancer 
and treated with antibody-based anti-EGFR monotherapy were used as samples. 
 





MicroRNAs (miRNAs) are short 18-25 nucleotide-long, single stranded, non-coding RNA 
molecules (1). MiRNAs act as post-transcriptional regulators of gene expression through 
induction of translational repression or RNA decay (2). MiRNAs play an important role in a 
wide range of normal physiological and pathological processes (3) (4). Aberrantly expressed 
miRNAs contribute to the development of various human disorders including cancers, 
neurodegenerative disorders, and autoimmune diseases (5) (6). 
Unlike mRNAs, miRNAs are highly stable and well preserved RNA molecules in formalin-
fixed paraffin-embedded (FFPE) samples and different body fluids including plasma, saliva 
and urine (7) (8) (9). The high stability as well as their disease-specific expression pattern 
renders miRNAs suitable for biomarkers in molecular diagnostic applications. Recently, 
miRNAs have been investigated as potential diagnostic and prognostic markers in patients 
suffering of cancer and autoimmune diseases by using samples of various origin, like FFPE, 
plasma, and urine (10) (11) (12) (13). Interestingly, a miRNA expression profile is equally 
useful for identifying tissue origin of tumors, subtype classifications of different cancers, 
prediction of clinical outcome, and selection of patients for targeted therapy (14) (15) (16) 
(17) (18) (19). 
Stem-loop RT-qPCR is a widely used technique for detection and quantification of mature 
miRNAs (20). This method includes two steps: 1. miRNA specific stem-loop RT primer-
based reverse transcription, and 2. quantification of product using conventional TaqManTM 
assay with miRNA specific TaqManTM probe and forward primer. This method enables us to 
quantify mature miRNA expression levels from nanograms of total RNA (20). A simplified 
setup of stem-loop RT-qPCR uses a general stem-loop primer specific probe from the 
Universal Probe Library (UPL, Roche Applied Science) for quantification of RT products 
without loss of specificity and efficiency (21). More recently, we developed a novel UPL 
probe-based stem-loop RT-qPCR assay design software (MiRNA Primer Design Tool, freely 
available online at: http://genomics.dote.hu:8080/mirnadesigntool/) that enables anyone to 
design the stem loop and specific primers needed for the assay. The MiRNA Primer Design 
Tool was validated in various species and experimental conditions (22). The method broadens 
the application of the stem-loop primer-based miRNA quantitation to virtually any species or 
variant of small regulatory RNA molecules.  
Here we present a detailed protocol for a UPL probe-based stem-loop RT-qPCR assay. We 
used this method to quantify hsa-miR-515-3p, hsa-miR-325, and hsa-miR-155 using the small 
nucleolar RNA RNU43 as a normalization control. Human urines from healthy pregnant 
donors as well as FFPE samples from patients diagnosed with colorectal cancer were analyzed 
using the method described here. 
2. Materials  
2.1. Urine samples 
Urine samples were collected from pregnant women during a prospective study in the 
Department of Obstetrics and Gynecology, University of Debrecen, Hungary. Samples were 
collected according to rules and regulations of the University of Debrecen, Medical and 
Health Science Center, with the approval of the local ethics committee (file number: 
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DEOEC RKEB/IKEB 3092-2010). All patients were informed about the purpose of sample 
collection and signed an informed consent form. 
 
2.2. FFPE samples 
FFPE samples were obtained during routine diagnostic procedures for histological and 
molecular analysis performed in the Department of Pathology, University of Debrecen. All 
samples had KRAS mutant genotype confirmed by capillary sequencing and were divided 
into two groups of five patients according to disease-free survival after anti-EGFR therapy 
(good and poor responders). Samples were collected according to rules and regulations of the 
University of Debrecen, Medical and Health Science Center, with the approval of the local 
ethics committee (file number: RKEB/IKEB 3856-2013).  
2.3. Reagents and equipments  
1. The High Pure miRNA Isolation Kit is used to prepare small RNA (Roche Applied 
Science). Before miRNA isolation prepare the following buffers: 
• 20% Binding Buffer: for each sample, mix 80 µl of Binding Buffer (from the High 
Pure miRNA Isolation Kit) with 320 µl of nuclease-free water (NFW) in a sterile, 
nuclease-free 15 ml centrifuge tube. (see Note 1). 
• Wash Buffer: if the High Pure miRNA Isolation Kit is freshly opened, prior of the 
first use, add 40 ml absolute ethanol. 
• Tissue Lysis Buffer: 100 !l Paraffin Tissue Lysis Buffer, 8 !l 20% SDS, and 40 !l 
Proteinase K working solution per sample. 
2. Transcriptor First strand cDNA Synthesis Kit (Roche Applied Science)  
3. First Strand cDNA Synthesis kit for RT-PCR (AMV) (Roche Applied Science)  
4. Sodium dodecyl sulfate (SDS) 
5. Xylene (Sigma-Aldrich) 
6. Absolute ethanol 
7.Nuclease-free water (NFW, Lonza) 
8. Microcentrifuge with centrifugal force of 15,000 xg 
9. Microcentrifuge tubes (1.5 ml) 
10. 0.2 ml PCR strip (Axygene) 
11. Eppendorf Thermomixer comfort 
12. Microcentrifuge Combi Spin FVL-2400N 
13. Agilent 2100 Bioanalyzer and a Small RNA Chip (Agilent Technologies) 
14. Applied Biosystems 2720 Thermal Cycler 
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15. Roche LightCycler 480 QPCR System 
16. Roche LightCycler 480 compatible qPCR plates 
17. The assays used for the QPCR measurements were designed by using the MiRNA Primer 
Design Tool at: http://genomics.dote.hu:8080/mirnadesigntool/. (see Note 2). 
 
3. Methods 
3.1 Sample preparation and requirements 
Collected urine samples should be stored temporarily at 4 °C. Samples are centrifuged at 
3,000 xg for 10 min to remove cellular debris. The supernatant is transferred to 1.5 ml pre-
labeled screw tubes (sterile), and stored at -75 to -80 °C.  
Regarding your FFPE samples: use only tumor blocks with malignant cell content higher than 
30%. A dedicated pathologist should evaluate the tumor cell content of the paraffin embedded 
blocks. For each sample to be measured by QPCR, miRNA isolation should be carried out 
from five pieces of 4 !m-thick FFPE tumor slices and their adjacent non-tumorous tissues.  
 
3.2. Small RNA/miRNA preparation protocol from urine samples 
Urine samples can be frozen and stored at -70oC until isolation process. Samples should be 
thawed slowly and kept on ice (see Notes 3-7). 
1. Under a chemical fume hood, mix 150 µl of urine with 312 µl of 20% Binding 
Buffer in a 1.5 ml microcentrifuge tube (see Note 1). Mix the solutions by vortexing. 
2. Pour the mixture into a High Pure filter tube. 
3. Place your filter tube into a clean 1.5 ml microcentrifuge tube. 
4. Centrifuge at 15,000 xg for 1 min at room temperature. Collect the flow-through in a 
clean 1.5 ml microcentrifuge tube. 
5. Add 200 µl Binding Enhancer to the flow-through, and mix well by vortexing. This 
fraction contains your microRNAs.   
6. Add the mixture to a new High Pure filter tube. 
7. Centrifuge at 15,000 xg for 1 min. 
8. Discard the flow-through.  
9. Add 500 µl of Wash Buffer and centrifuge columns at 15,000 xg for 1 min. 
10. Repeat the washing steps 8 and 9. 
11. Transfer High Pure Filter columns into a new collection tube and centrifuge at 
15,000 xg for 2 min to completely dry the filter fleece.  
12. Place High Pure filter tube in a new 1.5ml microcentrifuge tube. 
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13. Add 50 µl of Elution Buffer to the top of the filter and wait for 1 min.  
14. Centrifuge at 15,000 xg for 1 min to elute the purified miRNAs. 
15. Store samples below -20°C. 
16. For miRNA isolation from higher amount of urine, see Note 8. 
 
3.3. miRNA preparation from FFPE samples  
Tumor slices from FFPE (formalin-fixed, paraffin-embedded) blocks can be obtained by 
microtome dissection and should be collected in 1.5ml microcentrifuge tubes as shown in 
Figure 1. Five slices of 4 µm thickness should be combined in one microcentrifuge tube (see 
Note 9). For nucleic acid isolation, Xylene deparaffinization is used with subsequent washing 
by absolute ethanol. The deparaffinization steps should be performed 4-5 times to remove all 
the paraffin from samples. All steps of deparaffinization are recommended to be done under a 
chemical fume hood; solutions can be stored at room temperature.  
(Figure 1.) 
 
Perform miRNA isolation using the Roche High Pure miRNA Isolation Kit as it follows. 
Day 1: Deparaffinization 
1. Add 1 ml Xylene to each sample and incubate for 5 min at 56°C in a thermomixer at 
800 rpm. 
2. Centrifuge the samples for 2 min at 15,000 xg. 
3.  Discard supernatant containing xylene (see Note 10). 
4. Add 1 ml absolute ethanol. 
5. Vortex for 10 seconds. 
6.  Centrifuge for 2 min at 15,000 xg.  
7. Discard supernatant containing absolute ethanol with traces of xylene. 
8. Repeat steps 4-7 at a minimum of two times.  
9. If tumor mass is larger than 30% of the slice, repeat steps 1-3 at least two times, then 
proceed to steps 4-7 and repeat ethanol washing for four times.  
10. Dry the samples at 56°C for 15 min with the centrifuge tube lid open to rid of residual 
ethanol (see Note 11). 
11. Add Tissue Lysis Buffer solution.  
12. Vortex and incubate at 55 °C overnight. 
 
Day 2: miRNA isolation  
13. Centrifuge samples for 5 min, 15,000 xg at room temperature. 
14. Transfer supernatant to a new microcentrifuge tube. 
15. Add 325 !l 20% Binding Buffer working solution and vortex briefly. 
16. Add 120 !l Binding enhancer and vortex briefly. 
17. Pipette mixtures into High Pure filter columns.  
18. Centrifuge at 15,000 xg for 1 min and collect the flow-through. This fraction contains 
your miRNAs. 
19. Add 205 !l Binding Enhancer to flow-through and vortex. 
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20. Pipette mixtures onto a new High Pure filter column. 
21. Centrifuge at 15,000 xg for 1 min and discard the flow-through. 
22. Add 500 !l Wash Buffer and centrifuge at 15,000 xg for 1 min and discard the flow-
through. 
23. Add 300!l Wash Buffer and centrifuge at 15,000 xg for 1 min and discard the flow-
through. 
24. Centrifuge at 15,000 xg for 2 min to completely dry the filter fleece. 
25. Place the High Pure filter tube into a fresh 1.5 ml microcentrifuge tube, and then add 
50 !L Elution Buffer and incubate for 1 min at room temperature.  
26. Centrifuge for 1 min at 15,000 xg. 
#() The flow-through contains the isolated miRNA, which can be stored at -20°C.!
 
3.4. RNA quality control and yield 
For detection of miRNA content of the isolated samples and for quality control, use an 
Agilent Bioanalyzer 2100 System (Agilent Technologies) with a Small RNA Agilent Chip.  
Perform the run according to the instructions of the manufacturer.  
The report will contain the amount of RNA purified and the percentage of miRNA in the 
purified fraction. Sensitivity of the Agilent microchip kit is 50 pg/µl for the 40 bp fraction. 
Representative results of the analysis are shown on Figure 2. (see Notes 12-17) 
The yield of isolated miRNAs is donor dependent. Table 1 represents the concentrations of 
miRNAs from human urine samples. 
 
(Figure 2.)  
(Table 1) 
3.5. Quantification of miRNA by qPCR 
For quantification of specific miRNAs, the first step of cDNA synthesis is followed by PCR 
amplification using the Real Time Quantitative method (qPCR). Design primers using the 
UPL probe-based stem-loop quantitative PCR assay design software located at: 
http://genomics.dote.hu:8080/mirnadesigntool/ (see Notes 2, 18, 19). 
 
3.5.1. cDNA Synthesis: 
Option A: recommended for miRNA with low or unknown expression levels 
Transcribe miRNAs using the Transcriptor First strand cDNA Synthesis kit and a final stem-
loop primer concentration of 50 nM. Use miRNA templates diluted to 10 ng/µl. 
1. Prepare the following Annealing Mix: 
• miRNA [10 ng/µl]:    1 µl 
• Stem-loop RT primer [1 µM]: 1 µl 
• NFW      11 µl 
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• Total:     13 µl/reaction 
If processing more than 8 samples, prepare a mastermix with a minimum of 10% excess (see 
Note 20). Mix components in a 0.2 ml PCR strip by pipetting up and down five times and 
spin briefly in a Combi Spin microcentrifuge.  
 
2. Incubate samples for 10 min at 65 °C in an Applied Biosystems 2720 Thermal Cycler (see 
Notes 3-7). 
3. For each reaction, prepare the RT Mix as follows:  
• 5x reaction buffer:    4 µl 
• RNase inhibitor [40 U/µl]:   0.5 µl 
• 10 nM dNTP mix:    2 µl 
• RT enzyme:     0.5 µl 
• Total      7 µl/well 
4. Add the RT Mix to the Annealing mix in the 0.2 ml PCR strip, vortex and spin briefly (see 
Note 21). Perform the RT reaction on a thermocycler using the following thermal profile: 
• 50 °C 60 min 
• 85 °C 5 min 
• 4 °C " 
 
Option B: recommended for miRNA with relatively high expression levels 
A more rapid protocol can be used to reverse transcribe miRNAs with high expression level. 
This method uses the First Strand cDNA synthesis kit for RT-PCR (AMV) that has shorter 
hands-on time but lower sensitivity (higher average crossing point (Cp) values); therefore it 
should be used only for miRNAs with relatively high expression levels. On Figure 3 the 
performance of the two different options is shown.  
(Figure 3.)  
 
1. If processing more than 8 samples, prepare a mastermix containing all components of the 
reaction listed below except your miRNA sample (see Note 20). Prepare separate 
mastermix for the measured miRNA and the normalizer miRNA. It is advisable to 
measure the normalizer and the target miRNA on the same qPCR plate from the same 
batch of reagents. (see Note 3-7). In this setup, a separate annealing step is not needed. 
(see Note 21) 
Mix the following components per sample: 
• miRNA [10 ng/µl]:    1 µl 
• 25 mM MgCl2:    4 µl 
• 10X buffer:     2 µl 
• stem-loop RT primer [100 µM]:  0.2 µl 
• RNase inhibitor:    1 µl 
• RT Enzyme:     0.8 µl 
• NFW:      11 µl 
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• Total:     20 µl/well 
2. Perform the RT reaction on a thermocycler using the following thermal profile: 
• 25 °C 10 min 
• 42 °C 60 min 
• 99 °C 5 min 
• 4 °C " 
 
3.5.2. qPCR amplification 
1. Dilute reverse transcribed miRNA two-fold with NFW (see Note 3-7). 
2. Prepare qPCR mix in triplicate for each RT reaction. Components for one single qPCR 
reaction are:  
• NFW:          10.28 µl 
• 25 mM MgCl2 (Fermentas):         2 µl 
• 10X buffer (Fermentas, MgCl2 free buffer):      1.6 µl  
• 2.5 mM dNTP (Fermentas):                     0.8 µl 
• miRNA specific Forward primer [100 µM]:       0.06 µl 
• Universal Reverse primer [100 µM]:         0.06 µl 
• UPL Probe 21:            0.1 µl 
• Taq Polymerase [5U/µl] (Fermentas):         0.1 µl  
           Total:          15 µl/well 
3. Mix 5µl of the two-fold diluted reverse transcribed miRNA with 15µl qPCR mix /reaction. 
Perform all qPCR measurements in triplicate. (see Notes 20, 22-24) 
4. Run the qPCR amplification in a thermo cycler using the following temperature profile: 
• 95 °C 3 min  
• 95 °C 10 sec 
• 58 °C 30 sec 
• 72 °C 1 sec 
• repeat steps 2 to 4 for 45 cycles 
• 40 °C 10 min 
5. Collect data from fluorescence signal at step 3 in “Single mode”. (see Notes 25-29) 
 
We quantified miR-155 using this protocol and RNU43 as endogenous control. Our results 
correlate with previously published results (23) and suggest that in colorectal cancer increased 
levels of miR-155 might predict a better overall survival (OS) and disease-free survival (DFS) 
after treatment with anti-EGFR therapy. Results of the measurements are presented in Figure 
4. Due to the low number of samples (five independent samples per group), the presented 
results are not statistically significant and further investigation is needed.  
(Figure 4.) 
4. Notes  
1. Guanidine-thiocyanate in Binding Buffer may form toxic gases; therefore, perform the 
! +!
dilution step under a chemical fume hood 
2. Preparatory steps for the protocol: 
• Select your target miRNA sequence from mirBase (http://mirbase.org/) or from your 
next-generation sequencing dataset. (E.g. hsa-mir-155: 
UUAAUGCUAAUCGUGAUAGGGGU). Use the identified sequence to design your 
assay at: http://genomics.dote.hu:8080/mirnadesigntool/  
Useful information and details on how to use the software have been collected and 
stored at our dedicated website: http://genomics.med.unideb.hu/en/research-
interest/mirna-research. The MiRNA Primer Design Tool can be used freely under 
GNU/GPL license and installed on local servers from the following location: 
https://github.com/lbalintatmedunidebhu/mirnaprimerdesigntool 
• During selection of your target, perform a sequence search in the miRBase database 
to idetify microRNAs with similar sequences. If similar sequences on the 3’ end are 
present, evaluate your assays for differences in the other regions and consider using 
alternative methods for detection. 
• Order your stem loop oligo by HPLC purification. All other oligos used can be of 
standard desalted purification. !
3. Always work with samples kept on ice. 
4. Work in RNase-free conditions. 
5. Always wear gloves. 
6. Use only nuclease-free water. 
7. Use RNase-free plasticware. 
8. A higher amount of body fluid can be used if the miRNA concetration is too low. It is 
important to keep the same proportion of urine sample and Binding Buffer. For example, 
add 920 µl Binding Buffer to 450 µl urine, and repeat the binding steps to the column 
(steps 5 to 8).  
9. During microtome dissection of the FFPE blocks, carefully clean tweezers with nuclease-
free water and 70% ethanol to exclude ribonucleic acid transfer and contamination 
between samples. 
10. Xylene should be discarded according to the local rules of waste management. Xylene is 
an organic solvent and should be treated as a chemically hazardous waste. 
11. To remove all the supernatant during deparaffinization, additional centrifugation steps can 
be performed. 
12. The Agilent small RNA kit contains a highly viscousus gel and, therefore, it is essential to 
pipette carefully. 
13. If your sample contains significant amounts of tRNA then you will observe a 60 nt band 
in chromatogram of the Agilent Bioanalyzer run (24). 
14. Specific miRNA concentrations can be measured only by an Agilent Bioanalyzer miRNA 
microchip. Due to the lower sensitivity, Nanodrop or Qubit systems are not appropriate.  
15. If starting with a sample isolated from cells or tissues, the initial material should be 
between 5 ng and 50 ng of total RNA per RT reaction. This value stands for total RNA 
isolated by Trireagent. The concentration of total RNA mentioned here was measured by 
Nanodrop or Qubit systems due to the fact that beside the miRNA-s it contains all the 
other RNA fractions of a cell. 
16. When using a specific miRNA isolation protocol, this starting material can be much lower 
and should be optimized for each sample type. 
17. Conventional, non miRNA optimized column-based RNA purification methods are not 
suitable for microRNA purification since they are optimized for larger RNA molecules 
and the low molecular weight fraction of miRNA-s are not bound to the column.  
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18. Universal Reverse Primer and the UPL probe 21 can be used with all your assays designed 
with the previously presented miRNA Primer Design Tool. 
19. Each assay should be tested on a sample known to contain your miRNA of interest. 
20. For the PCR step, if processing more than 8 samples, prepare a Mastermix. Always 
calculate the volumes for your mastermix with a minimum of 10% excess. 
21. Perform a No Amplification Control (NAC) by leaving out the RT (reverse transcription) 
enzyme. Your NAC control should be at least a 3.33-CP higher value (meaning lower 
signal) than your control. Some background noise is acceptable but it should be less than 
10% of your signal (3.33 CP would mean 10% signal with an optimal PCR efficiency). 
22. You can test efficiency of your qPCR by performing a qPCR on a dilution series of 10-
fold dilutions steps that cover five orders of magnitude. 
23.  At the qPCR step, always perform a No Templare control (NTC) by replacing your 
reverse transcribed sample with nuclease-free water. 
24. qPCR step should be performed in triplicate (three technical replicates). 
25. Normalizers should be carefully selected by measuring their expression levels across 
several samples used in your experiment. Usually small nucleolar RNAs (snoRNAs) and 
nuclear RNAs like U6 can be used after careful consideration. 
26. Normalization should be performed with the delta delta !!CT method !"#$. 
27. If working with body fluids, you can normalize your sample to a relevant marker that 
reflects the changes in the concentration of the body fluid e.g. total protein concentration, 
density.  
28. If working with body fluids, the purification step can be controlled by adding spike-in 
artificial microRNA molecules to the sample. 
29. Synthetic RNA molecules can be used for carefully monitoring the efficiency of your 
reactions and to generate standard curves. If using synthetic RNA molecules as positive 
controlls for your reaction, order them separately from your assay components in order to 
avoid cross contamination at the manufacturing site. Dissolve them under a chemical 
hood. Keep them in separate locations compared than your assays, reagents and samples. 
The danger of contaminating your reagents with traces of the amplicon is extremely high. 
 
5. Acknowledgements 
Balint L. Balint is a Szodoray fellow of the University of Debrecen Medical and Health 
Science Center, Hungary and is supported by the TÁMOP 4.2.4.A/2-11-1-2012-0001 grant 
implemented through the New Hungary Development Plan co-financed by the European 
Social Fund and the European Regional Development Fund. Jim Hesson of 




1. Bartel DP (2004) MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116: 
281-297.  
2. Huntzinger E, Izaurralde E (2011) Gene silencing by microRNAs: contributions of 
translational repression and mRNA decay. Nat Rev Genet 12: 99-110.  
3. Ivey KN, Srivastava D (2010) MicroRNAs as regulators of differentiation and cell fate 
decisions. Cell Stem Cell 7: 36-41.  
4. Baltimore D, Boldin MP, O'Connell RM, et al. (2008) MicroRNAs: new regulators of 
immune cell development and function. Nat Immunol 9: 839-845.  
5. Tili E, Michaille JJ, Costinean S, et al. (2008) MicroRNAs, the immune system and 
rheumatic disease. Nat Clin Pract Rheumatol 4: 534-541.  
6. Du L, Pertsemlidis A (2011) Cancer and neurodegenerative disorders: pathogenic 
convergence through microRNA regulation. J Mol Cell Biol 3: 176-180.  
7. Weber JA, Baxter DH, Zhang S, et al. (2010) The microRNA spectrum in 12 body fluids. 
Clin Chem 56: 1733-1741.  
8. Xi Y, Nakajima G, Gavin E, et al. (2007) Systematic analysis of microRNA expression of 
RNA extracted from fresh frozen and formalin-fixed paraffin-embedded samples. RNA 13: 
1668-1674.  
9. Jung M, Schaefer A, Steiner I, et al. (2010) Robust microRNA stability in degraded RNA 
preparations from human tissue and cell samples. Clin Chem 56: 998-1006.  
10. Hui A, How C, Ito E, et al. (2011) Micro-RNAs as diagnostic or prognostic markers in 
human epithelial malignancies. BMC Cancer 11:500  
11. Mengual L, Lozano JJ, Ingelmo-Torres M, et al. (2013) Using microRNA profiling in 
urine samples to develop a non-invasive test for bladder cancer. Int J Cancer 133: 2631-2641. 
12. Shen N, Liang D, Tang Y, et al. (2012) MicroRNAs--novel regulators of systemic lupus 
erythematosus pathogenesis. Nat Rev Rheumatol 8: 701-709.  
13. Alevizos I, Illei GG (2010) MicroRNAs as biomarkers in rheumatic diseases. Nat Rev 
Rheumatol 6: 391-398.  
14. Mattie MD, Benz CC, Bowers J, et al. (2006) Optimized high-throughput microRNA 
expression profiling provides novel biomarker assessment of clinical prostate and breast 
cancer biopsies. Mol Cancer 5: 24.  
15. Rosenfeld N, Aharonov R, Meiri E, et al. (2008) MicroRNAs accurately identify cancer 
tissue origin. Nat Biotechnol 26: 462-469.  
16. Lu J, Getz G, Miska EA et al. (2005) MicroRNA expression profiles classify human 
cancers. Nature 435: 834-838.  
17. Takamizawa J, Konishi H, Yanagisawa K, et al. (2004) Reduced expression of the let-7 
microRNAs in human lung cancers in association with shortened postoperative survival. 
Cancer Res 64: 3753-3756.  
18. Hayashita Y, Osada H, Tatematsu Y, et al. (2005) A polycistronic microRNA cluster, 
miR-17-92, is overexpressed in human lung cancers and enhances cell proliferation. Cancer 
Res 65: 9628-9632.  
19. Chen JQ, Russo J (2009) ERalpha-negative and triple negative breast cancer: molecular 
features and potential therapeutic approaches. Biochim Biophys Acta 1796: 162-175.  
20. Chen C, Ridzon DA, Broomer AJ, et al. (2005) Real-time quantification of microRNAs by 
stem-loop RT-PCR. Nucleic Acids Res 33: e179.  
21. Varkonyi-Gasic E, Wu R, Wood M, et al. (2007) Protocol: a highly sensitive RT-PCR 
method for detection and quantification of microRNAs. Plant Methods 3: 12.  
! "#!
22. Czimmerer Z, Hulvely J, Simandi Z, et al. (2013) A versatile method to design stem-loop 
primer-based quantitative PCR assays for detecting small regulatory RNA molecules. PLoS 
One 8: e55168.  
23. Shibuya H, Iinuma H, Shimada R, et al. Clinicopathological and prognostic value of 
microRNA-21 and microRNA-155 in colorectal cancer. Oncology 79: 313-320.  
24. Becker C, Hammerle-Fickinger A, Riedmaier I, et al. mRNA and microRNA quality 
control for RT-qPCR analysis. Methods 50: 237-243.  
25. Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time 




Figure 1. FFPE sample preparation for deparaffinization. A. FFPE blocks were sectioned 
with microtome. B and C. Individual slices were removed from the microtome and placed into 
1.5 ml microcentrifuge tubes. D. Marginal area of a moderately differentiated colorectal 
adenocarcinoma with a tubular architecture and mucin production showing invasion through 
the muscular layer of the bowel wall (HE staining, 20 fold magnification). The normal 
colorectal epithelium is visible on the left side of the picture. The importance of the 
histological selection relies on accurate identification and enrichment of tumor tissue in FFPE 
samples applied for molecular testing. 
Figure 2. Assessment of urinary miRNA concentration and quality using the Agilent 2100 
bioanalyzer and associated Small RNA Agilent Chip.    
 
Figure 3. Comparison of two different RT-QPCR methods. Ten nanograms of miRNA were 
reverse transcribed by Transcriptor First Strand cDNA Synthesis kit (Transcriptor) or First 
Strand cDNA Synthesis kit for RT-PCR (AMV) according to Kit protocols. Cp values of the 
RT-qPCR measurements for hsa-miR515-3p and hsa-miR-325 from urine sample of one 
representative donor are shown. Error bars represent the SD value of the qPCR triplicates. 
Figure 4. Relative expression of miR-155 normalized to RNU43 in colorectal 
adenocarcinoma. miR-155 expression profile of 5-5 good and poor responder patients with 







Table1: miRNA content of urine samples.  
 
 
Sample name miRNA/Small RNA Concentration pg/µl 
purified RNA 
mi312/450 µl 20% 3115,8 
mi312/150 µl 30% 1043,6 
mi313/450 µl 39% 1553,7 
mi313/150 µl 40% 823,4 
mi314/450 µl 28% 454,2 
mi314/150 µl 53% 474,6 
mi315/450 µl 41% 144,7 
mi315/150 µl 28% 7,7 
mi5/450 µl 54% 573,5 
mi5/150 µl 34% 117,2 
Sample name column indicates the volume of urine used for miRNA purification.. 
